CAMPBELL, Calif., July 21, 2025 /PRNewswire/ --Semler Scientific, Inc. (Nasdaq: SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and a leader in medical devices and software to combat chronic diseases, today announced it will report financial results for the second quarter ended June 30, 2025, after the close of U.S. financial markets on Monday, August 4, 2025. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a live video webinar at 4:30 pm ET the same day. Eric Semler, executive chairman, Renae Cormier, chief financial officer, and Joe Burnett, director of Bitcoin strategy, will join him on the call. Please submit questions prior to the start of the call to This email address is being protected from spambots. You need JavaScript enabled to view it..

A live video webinar of the event can be accessed at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=GSe0xNiE. The live video webinar will also be live streamed on The Bitcoin for Corporations YouTube page at https://www.youtube.com/@BitcoinforCorporations.

Those without internet access may dial in by calling one of the following numbers and specify to the operator that you would like to join the "Semler Scientific Call":
Domestic callers: 833-816-1161
International callers: 412-317-0717

The video webinar will be archived on Semler Scientific's website at www.semlerscientific.com.

About Semler Scientific, Inc.:

Semler Scientific, Inc. is the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and is a leader in medical devices and software to combat chronic diseases.  By using proceeds from equity and debt financings, as well as cash flows from operations, Semler Scientific intends to strategically accumulate Bitcoin. In addition, through its healthcare businesses, Semler Scientific and its wholly-owned subsidiary, CardioVanta, Inc., develop and market products and services for early detection and monitoring of chronic diseases. Semler Scientific's flagship product, QuantaFlo, which is patented and cleared by the U.S. Food and Drug Administration (FDA), provides rapid point-of-care testing to measure arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of peripheral arterial disease. Additional information about Semler Scientific can be found at www.semlerscientific.com.

INVESTOR CONTACT:

Renae Cormier
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.